Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0425 (+1.43%)
USRM Successfully Launches Stem Cell Webinar Series

Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0425 (+1.43%)
USRM Successfully Launches Stem Cell Webinar Series

SUNRISE, Fla. , Feb. 12, 2018 /PRNewswire/ -- Dr. Kristin Comella , Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem...

USRM : 0.0425 (+1.43%)
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive...

USRM : 0.0425 (+1.43%)
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

SUNRISE, Fla. , Feb. 6, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0425 (+1.43%)
USRM Chief Science Officer Featured in Powerful Stem Cell Docuseries

SUNRISE, Fla. , Jan. 24, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0425 (+1.43%)
USRM Reaches Key Sales Milestone of Proprietary Adipocell(TM) Product

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone...

USRM : 0.0425 (+1.43%)
USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function

SUNRISE, Fla. , Jan. 8, 2018 /PRNewswire/ --  U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0425 (+1.43%)
USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert...

USRM : 0.0425 (+1.43%)
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments

MIAMI , Dec. 20, 2017 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0425 (+1.43%)
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week...

USRM : 0.0425 (+1.43%)
Degenerative Disc Patients Significantly Improve with USRM's Adipocell(TM)

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Chief Science...

USRM : 0.0425 (+1.43%)
U.S. Stem Cell Responds to FDA's Regenerative Medicine Guidelines

U.S. Stem Cell, Inc. (OTC: USRM), a leader in development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to the recently-announced...

USRM : 0.0425 (+1.43%)
U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds

SUNRISE, FL / ACCESSWIRE / August 28, 2017 / The U.S. Food and Drug Administration today posted a warning letter issued to US Stem Cell Clinic (USCC), a privately-held Florida LLC and leader in novel regenerative...

USRM : 0.0425 (+1.43%)

Van Meerten Stock Picks

Market trading below its 150 DMA
Summary52% of the market is trading below its 150 DMA.
IWV +0.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.18%) this morning are up +0.17% at a 1 -1 /2 week high and European stocks are up +0.74% at a 1-week high. Strength in crude oil and metals prices has fueled a rally in energy and mining... Read More

Chart of the Day

Abiomed (ABMD) is the Barchart Chart of the Day.  The medical instrument company has a Trend Spotter buy signal, a Weighted Alpha o 139.67+ and gained 132.53% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the Friday session with fractional losses, as nearby March was 1.52% higher on the week. The USDA reported a private export sale of 116,000 MT of 17/18 corn to Japan through their daily reporting system this morning. Export commit...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.